A Phase 1 interventional study of varenicline and varenicline in Healthy and Non-Smoking, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 65 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-06-02.
Sponsored by Pfizer · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy, Elderly (65-85 years inclusive), Non-smoker
Exclusion Criteria:
Creatinine Clearnace \< 30 ml/min, Evidence or history of , unstable diseases
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: varenicline
Drug: varenicline
Drug: varenicline
Drug: Placebo
0.5 mg once daily for 7days followed by 0.5 mg twice daily for 7days followed by 1mg twice daily for 7 days
Also known as: Champix, Chantix
0.5 mg once daily for 14 days followed by 1 mg once daily for 7 days
Also known as: Champix, Chantix
0.5 mg once daily for 14 days followed by 0.5 mg twice daily for 7 days
Also known as: Champix, Chantix
Placebo for 21 days
Tolerability and safety (adverse events, electrocardiogram, vital signs, clinical safety labs, self reported nausea visual analogue scales)
Time frame: 21 days
Steady state pharmacokinetics
Time frame: 21 days
Effects on cognition (computerized battery of cognitive tests)
Time frame: 21 days
No secondary outcomes.
Time frame: Time frame n/a
The record gives a start of Apr 2008, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline